DK0642798T3 - Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater deraf - Google Patents
Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater derafInfo
- Publication number
- DK0642798T3 DK0642798T3 DK93309720T DK93309720T DK0642798T3 DK 0642798 T3 DK0642798 T3 DK 0642798T3 DK 93309720 T DK93309720 T DK 93309720T DK 93309720 T DK93309720 T DK 93309720T DK 0642798 T3 DK0642798 T3 DK 0642798T3
- Authority
- DK
- Denmark
- Prior art keywords
- conjugates
- polymeric
- platform molecules
- chemically defined
- chemically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyesters Or Polycarbonates (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/118,055 US6060056A (en) | 1991-02-08 | 1993-09-08 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule |
| US14259893A | 1993-10-22 | 1993-10-22 | |
| US08/152,506 US5552391A (en) | 1990-01-16 | 1993-11-15 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| EP93309288 | 1993-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0642798T3 true DK0642798T3 (da) | 2007-09-10 |
Family
ID=38015477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93309720T DK0642798T3 (da) | 1993-09-08 | 1993-12-03 | Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater deraf |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP1808183A3 (de) |
| AT (1) | ATE359830T1 (de) |
| DE (1) | DE69334133T2 (de) |
| DK (1) | DK0642798T3 (de) |
| ES (1) | ES2282988T3 (de) |
| HK (1) | HK1014240A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| ATE359830T1 (de) * | 1993-09-08 | 2007-05-15 | Jolla Pharma | Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten |
| US6410775B1 (en) | 1995-06-07 | 2002-06-25 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| US5874409A (en) * | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| ES2163648T3 (es) * | 1995-08-03 | 2002-02-01 | Dade Behring Inc | Conjugados de quinidina y su uso en inmunoensayos. |
| WO1997046251A1 (en) * | 1996-06-06 | 1997-12-11 | Lajolla Pharmaceutical Company | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES |
| AU2980297A (en) * | 1996-06-10 | 1998-01-07 | Laboratory Of Molecular Biophotonics | Photocleavable cyclic oligonucleotide |
| US7094943B2 (en) | 1998-04-27 | 2006-08-22 | Hubert Köster | Solution phase biopolymer synthesis |
| US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| US6399578B1 (en) * | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
| KR20020022691A (ko) * | 1999-06-08 | 2002-03-27 | 와이즈먼 앤드루 | 아미노옥시기를 포함하는 원자가 플랫폼 분자 |
| EP1233791A2 (de) | 1999-11-28 | 2002-08-28 | La Jolla Pharmaceutical Company | Lupusbehandlungsverfahren basierend auf antikörperaffinität und screeningverfahren und die verwendete zusammensetzungen |
| EP1292337A2 (de) * | 2000-06-08 | 2003-03-19 | La Jolla Pharmaceutical | Polyethylenoxid mit hohem molekulargewicht enthaltende multivalenz-plattformmoleküle |
| EP3566719A1 (de) * | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Zusammensetzungen und verfahren zur behandlung von autoimmun- und anderen erkrankungen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987000056A1 (en) * | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4904582A (en) * | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5162515A (en) * | 1990-01-16 | 1992-11-10 | La Jolla Pharmaceutical Company | Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus |
| US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| ATE359830T1 (de) * | 1993-09-08 | 2007-05-15 | Jolla Pharma | Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten |
-
1993
- 1993-12-03 AT AT93309720T patent/ATE359830T1/de not_active IP Right Cessation
- 1993-12-03 EP EP07004965A patent/EP1808183A3/de not_active Withdrawn
- 1993-12-03 ES ES93309720T patent/ES2282988T3/es not_active Expired - Lifetime
- 1993-12-03 EP EP93309720A patent/EP0642798B1/de not_active Expired - Lifetime
- 1993-12-03 DK DK93309720T patent/DK0642798T3/da active
- 1993-12-03 DE DE69334133T patent/DE69334133T2/de not_active Expired - Fee Related
-
1998
- 1998-12-24 HK HK98115591A patent/HK1014240A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2282988T3 (es) | 2007-10-16 |
| EP0642798B1 (de) | 2007-04-18 |
| HK1014240A1 (en) | 1999-09-24 |
| ATE359830T1 (de) | 2007-05-15 |
| DE69334133T2 (de) | 2007-12-27 |
| EP0642798A2 (de) | 1995-03-15 |
| EP1808183A3 (de) | 2009-07-01 |
| EP0642798A3 (de) | 1998-09-16 |
| DE69334133D1 (de) | 2007-05-31 |
| EP1808183A2 (de) | 2007-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2171434A1 (en) | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | |
| DK0642798T3 (da) | Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater deraf | |
| DE68906984D1 (de) | Apparat zur durchfuehrung von sich wiederholenden chemischen reaktionen. | |
| DE69013282D1 (de) | Vorrichtung zur Durchführung und Regelung chemischer Reaktionen. | |
| AR243600A1 (es) | Un aparato para el tratamiento de muestras biologicas y microbiologicas. | |
| WO1999000494A3 (en) | Cell activation process and reagents therefor | |
| DE69120303D1 (de) | Konjugate aus biologisch stabilen Polymeren und Polynukleotiden zur Behandlung von systematischem Lupus erythematosus | |
| NO885275L (no) | Vaskulaere antikoagulantproteiner, dna'er som koder for dem, fremstilling og anvendelse derav. | |
| DE3861642D1 (de) | Katalysator zur wasserstoffbehandlung von kohlenwasserstoffen und methode zu dessen herstellung. | |
| ATE342911T1 (de) | Synthese von nukleosiden und polynukleotiden | |
| DE59703922D1 (de) | Vorrichtung zum homogenisieren, mischen und/oder granulieren von chemischen stoffen | |
| DE69804659D1 (de) | 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss | |
| DE69004037D1 (de) | Apparat zur Wärmebehandlung von kontaminiertem, stückigem Material. | |
| DE59203610D1 (de) | Reaktor zur Durchführung biologischer Reaktionen mittels Biokatalysatoren. | |
| DE69406236D1 (de) | Chemische Umwandlungsmethode und Oberflächenbehandlungsmethode für Metalldose | |
| NO900696D0 (no) | Fremgangsmaate og anordning for biologisk behandling omfattende nitrifisering og denitrifisering av avloepsvann. | |
| DE69616861D1 (de) | Vorrichtung zur Zerkleinern, Handhaben und Transportieren von Schrott | |
| DZ2094A1 (fr) | Appareil catalytique et/ou de filtration. | |
| EP0749312A4 (de) | DIROFILARIA IMMITIS - Gp29 - PROTEINE, NUKLEINSÄUREMOLEKÜLE UND IHRE VERWENDUNGEN | |
| ATE431361T1 (de) | Verwendung vom transportergen oatp-c zur screening von testsubstanzen | |
| DE69130845D1 (de) | HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung | |
| EP0634658A3 (de) | Biochemischer Analysator und Inkubator dafür. | |
| DE69101074D1 (de) | Niobtrisulfid-Katalysator zur Wasserstoffbehandlung von Kohlenwasserstoffeinsätzen und damit durchgeführtes Wasserstoffbehandlungsverfahren. | |
| EP0642021A3 (de) | Verfahren und Reagenz zur Messung der Komplementaktivität. | |
| DE3865794D1 (de) | Hydroraffinationskatalysator, ausgehend von hydrogelen, verfahren zur herstellung und verwendung. |